Publication Name	World Journal of Gastroenterology
Manuscript ID	27550
Country	Germany

Received	2016-06-04 14:19
Peer-Review Started	2016-06-05 09:58
To Make the First Decision	2016-06-20 10:52
Return for Revision	2016-06-28 09:21
Revised	2016-07-21 21:25
Second Decision	2016-08-05 10:18
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2016-08-10 15:48
Articles in Press	2016-08-10 15:48
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-09-01 14:21
Publish the Manuscript Online	2016-09-14 19:04

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Retrospective Cohort Study
Article Title	Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12
Manuscript Source	Invited Manuscript
All Author List	Christoph R Werner, Julia M Schwarz, Daniel P Egetemeyr, Robert Beck, Nisar P Malek, Ulrich M Lauer and Christoph P Berg
Funding Agency and Grant Number
Corresponding Author	Christoph P Berg, MD, Department of Gastroenterology, Hepatology, and Infectiology, University Hospital Tübingen, Otfried-Müller-Str. 10, 72076 Tübingen, Germany. christoph.berg@med.uni-tuebingen.de
Key Words	Sofosbuvir; Simeprevir; Ledipasvir; Hepatitis C; Liver transplant; Sustained virological response; Liver cirrhosis; Side effects; Resistance; Daclatasvir
Core Tip	From 2014 on the second wave of direct acting antiviral agents was available for treatment of chronic hepatitis C infection. Due to the more heterogeneous character of patients in the “real world”, the therapeutic performance of these new drugs outside randomized clinical trials is of interest. Therefore, in this monocentric retrospective cohort study, we analyzed the efficacy, safety, and predictors of sustained virological response 12 for treatment with combinations of second generation direct acting antivirals in a “real-world” setting.
Publish Date	2016-09-14 19:04
Citation	Werner CR, Schwarz JM, Egetemeyr DP, Beck R, Malek NP, Lauer UM, Berg CP. Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12. World J Gastroenterol 2016; 22(35): 8050-8059
URL	http://www.wjgnet.com/1007-9327/full/v22/i35/8050.htm
DOI	http://dx.doi.org/10.3748/wjg.v22.i35.8050

Full Article (PDF)	WJG-22-8050.pdf
Full Article (Word)	WJG-22-8050.doc
Manuscript File	27550-Review.docx
Answering Reviewers	27550-Answering reviewers.pdf
Audio Core Tip	27550-Audio core tip.wav
Biostatistics Review Certificate	27550-Biostatistics statement.PDF
Conflict-of-Interest Disclosure Form	27550-Conflict-of-interest statement.PDF
Copyright License Agreement	27550-Copyright assignment.PDF
Institutional Review Board Approval Form or Document	27550-Institutional review board statement.PDF
Non-Native Speakers of English Editing Certificate	27550-Language certificate.PDF
Peer-review Report	27550-Peer-review(s).pdf
Scientific Misconduct Check	27550-Scientific misconduct check.pdf
Scientific Editor Work List	27550-Scientific editor work list.pdf